Corporate Banner
Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ono Pharmaceutical Selects Genedata Expressionist for Mass Spectrometry

Published: Sunday, February 10, 2013
Last Updated: Saturday, February 09, 2013
Bookmark and Share
Global leader in drug discovery advances targeted proteomics and metabolomics with extended use of Genedata Expressionist®

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, has announced that Ono Pharmaceutical Co., Ltd.. (Ono) extended its Genedata collaboration with a license of Genedata Expressionist for Mass Spectrometry. Ono is a leading R&D-oriented international pharmaceutical company, which provides treatments for oncological and cardiovascular diseases. The Genedata Expressionist system, an enterprise and comprehensive platform for omics data management, will be used by Ono to further strengthen its targeted proteomics and metabolomics research.
 
"Our daily research demands accurate mass profiling analysis as well as powerful MRM capabilities for effective quantitative analysis," noted a spokesperson for the Tsukuba Research Institute at Ono. "Genedata Expressionist for Mass Spectrometry supports our proteomics and metabolomics research with a sophisticated data analysis platform that can process chromatograms ranging from 2MB to over 1GB.  And, the system's ability to integrate data from a variety of instruments is a valuable benefit to us. Finally, with Genedata Expressionist we can rely on superior algorithms that generate clinically relevant biomarkers supporting efficient research processes."
 
Experimental designs of molecular profiling studies in the life sciences are continually growing in complexity and size. Genedata Expressionist analyzes and manages genomic, transcriptomics, proteomics, metabolomics, and epigenomics data from leading technologies including next-generation sequencing, high-density microarrays, RT-PCR, and other genomic tools. Additionally, Genedata Expressionist enables integrated analysis and management of all major mass spectrometry (MS) profiling applications including a comprehensive solution for proteomic, metabolomics, and lipidomics data from all major MS technologies. With robust support of MRM data, the system's innovative capabilities include:
 
Data Visualization
Background Subtraction
Grid Alignment
Peak Detection
Annotation
 
"We are proud of our collaboration with Ono, one of the world's leading pharmaceutical companies providing innovative drug therapies," said Dr. Othmar Pfannes, CEO of Genedata. "With Genedata Expressionist and its support of innovative technologies such as MS and next-generation sequencing, we provide an integrative computational platform that supports customers such as Ono who are pioneering novel therapies. And, we are committed to continuous innovation by expanding the scope Genedata Expressionist applications in areas such as molecular diagnostics and personalized healthcare."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Boehringer Ingelheim Chooses Genedata Selector for Cell Line Development and Cell Culture Optimization
Company has announced that the leading pharma company to implement Genedata Selector as its global cell line and genome knowledge management platform.
Thursday, March 10, 2016
Genedata Signs License Agreement with AstraZeneca
Genedata Screener now AstraZeneca’s corporate platform for expediting drug discovery.
Saturday, November 21, 2015
Kymab Implements Genedata Biologics for High-throughput Antibody Discovery
Genedata Biologics™ integrated workflow platform used to increase throughput and automation of Kymab’s transgenic mice-based discovery platforms.
Tuesday, November 17, 2015
Genedata Completes Important Milestone in Collaboration with Bayer Pharma AG
Successful integration of Genedata Profiler™ allows researchers to access, process, analyze and manage petabytes of NGS and other omics data from patients and pre-clinical experiments.
Thursday, September 24, 2015
Merck Serono Chooses Genedata Biologics to Streamline Antibody Discovery Processes
Global deployment of Genedata Biologics across multiple protein therapeutics R&D groups to standardize workflows and improve efficiency.
Thursday, July 23, 2015
Genedata Releases a Breakthrough for Genomic Comparison
Genedata Selector™4.0 provides reference-independent genome sequence comparisons while reducing data processing and analysis time to optimize efficiency and save costs.
Wednesday, July 22, 2015
Genedata Forges Alliance with Intellicyt
Swiss informatics firm Genedata and Intellicyt today announced an alliance to work on cell-based screening in drug discovery.
Thursday, June 18, 2015
Precision Medicine Software Genedata Profiler™ Launched at Bio-IT World
Open, interoperable enterprise platform for patient and compound profiling provides important data management infrastructure for pharma internal R&D processes.
Friday, April 24, 2015
Partner on Innovative Workflow Platform for High-Throughput Cell Line Development
Novel Cell Line Development (CLD) data platform to support the generation and assessment of mammalian production cell lines.
Tuesday, March 17, 2015
Genedata, Bayer Pharma AG Partner on Innovative Workflow Platform for High-Throughput Cell Line Development
Novel Cell Line Development (CLD) data platform to support the generation and assessment of mammalian production cell lines.
Tuesday, March 17, 2015
Genedata Biologics Licensed by Pfizer
Pfizer implements Genedata Biologics to streamline global biopharma R&D processes.
Wednesday, March 04, 2015
Boehringer Ingelheim Selects Genedata Biologics as Antibody Discovery Workflow Platform
Genedata Biologics integrates and streamlines workflows for protein therapeutics R&D groups across multiple Boehringer Ingelheim sites.
Thursday, February 19, 2015
Exploring Innovations in SPR & Combination Screening
Genedata customers will discuss innovations in high content imaging, high throughput screening, compound combination screening, and other related topics at User Group Meetings.
Tuesday, August 26, 2014
GSK Implements Genedata Biologics as Antibody Discovery Platform
Genedata Biologics integrates GlaxoSmithKline's Biopharm Discovery workflows across multiple Biopharm R&D groups and sites
Thursday, June 12, 2014
Genedata Showcases Integrated Analysis & Image Management Solution for Phenotypic Screening
Regardless of instrument or application, Genedata Screener® for High Content Screening enables time-efficient workflow for analysis of high-content experiments
Friday, February 21, 2014
Scientific News
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Connectome Map More Than Doubles Human Cortex’s Known Regions
Researchers at NIH have developed software that automatically detects the “fingerprint” of each of these areas in an individual’s brain scans.
Virus Inspired Cell Cargo Ships
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Identifying Cancer Drug Targets Using 3D-Modelling
Researchers are now able to model genetic mutations manipulation of proteins that can potentially drive cancer.
Human Evolution Driven by Viruses
Study finds surprising percentage of protein adaptions in humans have been driven by viruses.
Earliest Sign of Alzheimer's Development Discovered
Researchers have identified the first physiological signs of late-onset Alzheimer's disease, underlining the importance of computational power in neurology.
Computational Method Offers Significant Boost in Finding New Cancer Targets
MIT and ARIAD Pharmaceuticals team have identified evidence of significant cancer mutations.
Drug Response Predicted by Cancer Cell Lines
Large-scale study could increase success rate of developing personalised cancer treatments.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!